Wilkieson C A, Madhok R, Hunter J A, Capell H A
Department of Rheumatology, Gartnavel General Hospital, Glasgow.
Q J Med. 1993 Aug;86(8):501-5. doi: 10.1093/qjmed/86.8.501.
Sulphasalazine is an effective second-line agent in the management of rheumatoid arthritis. The risk:benefit ratio in the elderly is less well established. We studied the risk:benefit ratio in relation to age, retrospectively combining five prospective studies of enteric coated sulphasalazine therapy in 352 patients with rheumatoid arthritis. Clinical and laboratory assessments of efficacy and toxicity were made by an independent assessor at 0, 12, 24 and 48 weeks. The only significant differences between young, middle aged and elderly patients at the initial assessment were in pain perception, ESR and C-reactive protein. Sulphasalazine was equally effective in all age groups. The toxicity profile was similar in all age groups. We conclude that sulphasalazine is equally effective in rheumatoid arthritis in the elderly as in the young. There was no significant change in the frequency or nature of side-effects with increasing age.
柳氮磺胺吡啶是类风湿关节炎治疗中一种有效的二线药物。在老年人中其风险效益比尚未明确。我们回顾性合并了五项关于肠溶包衣柳氮磺胺吡啶治疗352例类风湿关节炎患者的前瞻性研究，以研究与年龄相关的风险效益比。由一名独立评估人员在0、12、24和48周时对疗效和毒性进行临床和实验室评估。初始评估时，年轻、中年和老年患者之间唯一显著的差异在于疼痛感知、血沉和C反应蛋白。柳氮磺胺吡啶在所有年龄组中疗效相同。所有年龄组的毒性特征相似。我们得出结论，柳氮磺胺吡啶在老年人类风湿关节炎中的疗效与年轻人相同。随着年龄增长，副作用的频率和性质没有显著变化。
